Purchase this article with an account.
Jia Yu Yu Ng, Adriana Chilinska, Sayali Pradhan, Martina Althaus, Nusayhah Gopee, David Brass, James Langtry, Thomas Oliphant, Eric Barnes, Francisco C Figueiredo; Is pterygium an indicator of an increased risk of developing cutaneous melanoma? – Retrospective study in the UK. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3573.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the incidence of cutaneous melanoma (CM) amongst patients with visually significant pterygium in the North East of England; and compare cohort demographics with a previous study from a Western Australian population.
A retrospective, non-comparative, electronic clinical notes review. A list of all consecutive patients with surgically managed advanced pterygium between 2000 - 2018 in a single tertiary centre (Royal Victoria Infirmary, Newcastle upon Tyne) were obtained using linked health administrative data sets. Demographic data including age, sex ethnicity, pterygium characteristics (primary/recurrence, unilateral/bilateral and location), history of malignancy and systemic comorbidities were collected.
212 patients with pterygia underwent surgical intervention. The mean age for pterygium treatment was 51 (SD 15) years old, with a female to male ratio of 3:5. Of the 155 patients with documented ethnicity, 74% (n=115) were white, followed by 12% Asian (n=18), 5% Black (n=8) and 9% from other ethnicity (n=14). 56 (26%) had bilateral and 133 (63%) had unilateral pterygium. 23 (11%) had no documentation of side of pterygium. UV-related malignancy was found in 4 cases (1.9%), 3 patients (1.4%) had basal cell carcinoma and 1 patient (0.5%) had CM; non UV-related malignancies were found in 12 patients (5.7%).
Despite similar patient demographics to previous study from Western Australia (European white/Caucasian of similar age and sex distribution), the presence of a pterygium in North East England doesn’t appear to indicate an increased risk of developing a CM. Our study does not support the need for screening for CM amongst this patient group. This could be due to less total yearly solar ultraviolet radiation in the North East region (3240 standard erythemal dose (SEDs)) compared to Western Australia (8728 SEDs). Further multivariate study would help to identify high risk patients.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only